Module 9

Question 1

Which of the following would be the safest drug?
A. A drug with an ED50 that is much greater than the TD50.
B. A drug with a TD50 much greater than the ED50
C. A drug with an ED50 much greater than the LD50.
D. A drug with a small therapeutic index.

Answer 1

B. A drug with a TD50 much greater than the ED50

Question 2

Which of the following statements best describes the ED50?
A. The time it takes for 50% of the patients to reach maximal drug efficacy.
B. The dose of a drug that produces a response in 50% of the population.
C. The dose at which 50 percent of patients will have drug toxicity.
D. The number of doses it takes to achieve 50% of the response.

Answer 2

B. The dose of a drug that produces a response in 50% of the population.

Question 3

Which of the following statements is true when comparing the therapeutic index and the therapeutic range?
A. They are the same thing.
B. We use therapeutic drug monitoring to help guide dosing for drugs with a broad therapeutic index
C. The therapeutic index is a measure of a drug’s safety whereas the therapeutic range represents the plasma concentration in which the drug will produce a response without toxicity.
D. The therapeutic index is usually large for drugs that have a narrow therapeutic range.

Answer 3

C. The therapeutic index is a measure of a drug’s safety whereas the therapeutic range represents the plasma concentration in which the drug will produce a response without toxicity.

Question 4

In what phase of clinical trials are side effects and/or drug safety evaluated?
 A. Phase II
 B. Phase III
 C. Phase IV
 D. All are correct

Answer 4

D. All are correct

Question 5

Which one of the following statements is true?
A. Pharmacogenetics evaluates the differences in body composition on drug response.
B. Women respond better to drugs than men.
C. Race is a good predictor of drug response.
D. None are correct

Answer 5

D. None are correct

Question 6

Which of the following is an environmental factor that may cause patients to have a variable drug response?
 A. Diet
 B. Gender
 C. Polymorphisms
 D. All are correct

Answer 6

A. Diet

Question 7

Which of the following is true regarding kidney disease and drug responses?
A. Drugs usually have a shorter half-life in patients with kidney disease.
B. Doses of drugs are usually increased to compensate for decreased renal excretion.
C. Patients with kidney disease are likely to have higher plasma concentrations than healthy patients if doses are not adjusted.
D. Kidney disease causes an increase in the hepatic metabolism of drugs.

Answer 7

C. Patients with kidney disease are likely to have higher plasma concentrations than healthy patients if doses are not adjusted.

Question 8

You are asked to evaluate the safety of a new drug that has an LD50 of 3 mg/kg and a ED50 of 1 mcg/kg. The therapeutic index of this drug would be:
A. Small therefore the drug is dangerous.
B. Large therefore the drug is relatively safe.
C. Large therefore the drug is dangerous.
D. Small therefore the drug is relatively safe.

Answer 8

B. Large therefore the drug is relatively safe.

Question 9

Which of the following best represents the ED50?
A. The trough of a frequency distribution curve.
B. The peak of the frequency distribution curve.
C. The steady state plasma drug concentration.
D. None are correct.

Answer 9

B. The peak of the frequency distribution curve.

Question 10

Which of the following is the most important determinant of a patient’s dose?
A. The patient’s response.
B. How close the dose is to the ED50 of the drug.
C. The plasma concentration of the drug.
D. The therapeutic index of the drug.

Answer 10

A. The patient’s response.